These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26736734)

  • 1. Influences of gender and anthropometric features on inspiratory inhaler acoustics and peak inspiratory flow rate.
    Taylor TE; Holmes MS; Sulaiman I; Costello RW; Reilly RB
    Annu Int Conf IEEE Eng Med Biol Soc; 2015; 2015():2227-30. PubMed ID: 26736734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring Inhaler Inhalations Using an Acoustic Sensor Proximal to Inhaler Devices.
    Taylor TE; Holmes MS; Sulaiman I; Costello RW; Reilly RB
    J Aerosol Med Pulm Drug Deliv; 2016 Oct; 29(5):439-446. PubMed ID: 26859629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.
    Altman P; Wehbe L; Dederichs J; Guerin T; Ament B; Moronta MC; Pino AV; Goyal P
    BMC Pulm Med; 2018 Jun; 18(1):100. PubMed ID: 29898702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD.
    Ghosh S; Pleasants RA; Ohar JA; Donohue JF; Drummond MB
    Int J Chron Obstruct Pulmon Dis; 2019; 14():585-595. PubMed ID: 30880948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices.
    van der Palen J; Thomas M; Chrystyn H; Sharma RK; van der Valk PD; Goosens M; Wilkinson T; Stonham C; Chauhan AJ; Imber V; Zhu CQ; Svedsater H; Barnes NC
    NPJ Prim Care Respir Med; 2016 Nov; 26():16079. PubMed ID: 27883002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers.
    Broeders ME; Molema J; Vermue NA; Folgering HT
    Eur Respir J; 2001 Nov; 18(5):780-3. PubMed ID: 11757627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma.
    Hua JL; Ye XF; Du CL; Xie N; Zhang JQ; Li M; Zhang J
    BMC Pulm Med; 2021 Sep; 21(1):302. PubMed ID: 34560863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Inspiratory Maneuver Performance; Peak Lungpower, Acceleration and Volume.
    Haikarainen J; Vahteristo M; Lähelmä S; Vartiainen V; Malmberg LP
    J Aerosol Med Pulm Drug Deliv; 2020 Dec; 33(6):305-313. PubMed ID: 32423277
    [No Abstract]   [Full Text] [Related]  

  • 10. Can patients achieve sufficient peak inspiratory flow rate (PIFR) with Turbuhaler® during acute exacerbation of asthma?
    Mohd Rhazi NA; Muneswarao J; Abdul Aziz F; Ibrahim B; Kamalludin A; Soelar SA
    J Asthma; 2023 Aug; 60(8):1608-1612. PubMed ID: 36650693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.
    Ghosh S; Ohar JA; Drummond MB
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):381-387. PubMed ID: 28933581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ambulatory criteria of dry powder inhaler selection based on peak inspiratory flow recordings].
    Droszcz W; Droscez P
    Pneumonol Alergol Pol; 2002; 70(9-10):490-5. PubMed ID: 12710102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A method of estimating inspiratory flow rate and volume from an inhaler using acoustic measurements.
    Holmes MS; Seheult JN; Geraghty C; D'Arcy S; O'Brien U; Crispino O'Connell G; Costello RW; Reilly RB
    Physiol Meas; 2013 Aug; 34(8):903-14. PubMed ID: 23892977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The variability of peak inspiratory flow (PIF) on valves imitating dry powder inhalers resistance during asthma and COPD exacerbations].
    Grabowski M; Barg W; Chmielowicz B; Kopeć A; Panaszek B
    Pneumonol Alergol Pol; 2007; 75(4):324-30. PubMed ID: 18080981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients.
    Harb HS; Laz NI; Rabea H; Abdelrahim MEA
    Eur J Pharm Sci; 2020 Apr; 147():105298. PubMed ID: 32151707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea.
    Moon JY; Kim SH; Kim Y; Lee H; Rhee CK; Ra SW; Lee CY; Park JH; Park YB; Yoo KH
    Pulm Pharmacol Ther; 2024 Jun; 85():102298. PubMed ID: 38604404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults.
    Bronsky EA; Grossman J; Henis MJ; Gallo PP; Yegen U; Della Cioppa G; Kottakis J; Mehra S
    Curr Med Res Opin; 2004; 20(2):131-7. PubMed ID: 15006006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Repeatability of Inspiration Performance Through Different Inhalers in Patients with Chronic Obstructive Pulmonary Disease and Control Volunteers.
    Erdelyi T; Lazar Z; Odler B; Tamasi L; Müller V
    J Aerosol Med Pulm Drug Deliv; 2020 Oct; 33(5):271-281. PubMed ID: 32460588
    [No Abstract]   [Full Text] [Related]  

  • 20. Wixela Inhub: Dosing Performance
    Cooper A; Parker J; Berry M; Wallace R; Ward J; Allan R
    J Aerosol Med Pulm Drug Deliv; 2020 Dec; 33(6):323-341. PubMed ID: 32429788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.